Hung H M James, Wang Sue-Jane, O'Neill Robert
Division of Biometrics I, OB/OTS/CDER, US FDA, 10903 New Hampshire Ave, HFD-710, Silver Spring, MD 20993-0002, USA.
Biom J. 2009 Apr;51(2):324-34. doi: 10.1002/bimj.200800219.
For a non-inferiority trial without a placebo arm, the direct comparison between the test treatment and the selected positive control is in principle the only basis for statistical inference. Therefore, evaluating the test treatment relative to the non-existent placebo presents extreme challenges and requires some kind of bridging from the past to the present with no current placebo data. For such inference based partly on an indirect bridging manipulation, fixed margin method and synthesis method are the two widely discussed methods in the recent literature. There are major differences in statistical inference paradigm between the two methods. The fixed margin method employs the historical data that assess the performances of the active control versus a placebo to guide the selection of the non-inferiority margin. Such guidance is not part of the ultimate statistical inference in the non-inferiority trial. In contrast, the synthesis method connects the historical data to the non-inferiority trial data for making broader inferences relating the test treatment to the non-existent current placebo. On the other hand, the type I error rate associated with the direct comparison between the test treatment and the active control cannot shed any light on the appropriateness of the indirect inference for faring the test treatment against the non-existent placebo. This work explores an approach for assessing the impact of potential bias due to violation of a key statistical assumption to guide determination of the non-inferiority margin.
对于没有安慰剂组的非劣效性试验,试验治疗与选定的阳性对照之间的直接比较原则上是统计推断的唯一依据。因此,相对于不存在的安慰剂评估试验治疗带来了极大的挑战,并且在没有当前安慰剂数据的情况下需要某种从过去到现在的桥梁。对于这种部分基于间接桥梁操作的推断,固定界值法和综合法是近期文献中广泛讨论的两种方法。这两种方法在统计推断范式上存在重大差异。固定界值法利用评估活性对照与安慰剂性能的历史数据来指导非劣效界值的选择。这种指导并非非劣效性试验最终统计推断的一部分。相比之下,综合法将历史数据与非劣效性试验数据联系起来,以便对试验治疗与不存在的当前安慰剂进行更广泛的推断。另一方面,试验治疗与活性对照之间直接比较的I型错误率无法说明将试验治疗与不存在的安慰剂进行比较时间接推断的适当性。本研究探索了一种方法,用于评估因违反关键统计假设而导致的潜在偏差的影响,以指导非劣效界值的确定。